Treatments for secondary hyperparathyroidism in hemodialysis

被引：1
|
作者：
Cozzolino, Mario [1 ]
Messa, Piergiorgio [2 ,3 ]
机构：
[1] Univ Milan, Dept Hlth Sci, Div Renal, ASST Santi Paolo & Carlo, Milan, Italy
[2] Univ Milan, Div Nephrol, Maggiore Hosp, Milan, Italy
[3] Univ Milan, IRCCS Fdn, Milan, Italy
来源：
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ | 2017年 / 127卷 / 12期
关键词：
CHRONIC KIDNEY-DISEASE; PATIENTS RECEIVING HEMODIALYSIS; DISORDER CKD-MBD; VITAMIN-D; CINACALCET; PROGRESSION; DIALYSIS; CALCIUM; TRIAL;
D O I：
10.20452/pamw.4170
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：807 / 809
页数：3
相关论文
共 50 条
  • [1] Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
    Indridason, OS
    Quarles, LD
    KIDNEY INTERNATIONAL, 2000, 57 (01) : 282 - 292
  • [2] Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients
    Torres, P. A. Urena
    Bover, J.
    Cohen-Solal, M.
    DRUGS OF TODAY, 2017, 53 (09) : 489 - 500
  • [3] One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
    Bushinsky, David A.
    Chertow, Glenn M.
    Cheng, Sunfa
    Deng, Hongjie
    Kopyt, Nelson
    Martin, Kevin J.
    Rastogi, Anjay
    Urena-Torres, Pablo
    Vervloet, Marc
    Block, Geoffrey A.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (10) : 1769 - 1778
  • [4] Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
    Fang, Li
    Tang, Bing
    Hou, Dawei
    Meng, Meijuan
    Xiong, Mingxia
    Yang, Junwei
    BMC NEPHROLOGY, 2015, 16
  • [5] Secondary and Tertiary Hyperparathyroidism: A Narrative Review
    van der Plas, W. Y.
    Noltes, M. E.
    van Ginhoven, T. M.
    Kruijff, S.
    SCANDINAVIAN JOURNAL OF SURGERY, 2020, 109 (04) : 271 - 278
  • [6] A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)
    Itano, Yuya
    Kato, Sawako
    Tsuboi, Masato
    Kasuga, Hirotake
    Tsuruta, Yoshinari
    Sato, Fumihiko
    Hishida, Manabu
    Ishimoto, Takuji
    Kosugi, Tomoki
    Ando, Masahiko
    Kuwatsuka, Yachiyo
    Maruyama, Shoichi
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (12): : 2168 - 2177
  • [7] Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism A Randomized Placebo-Controlled Trial
    Shigematsu, Takashi
    Koiwa, Fumihiko
    Isaka, Yoshitaka
    Fukagawa, Masafumi
    Hagita, Keiko
    Watanabe, Yukihisa S.
    Honda, Daisuke
    Akizawa, Tadao
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (10): : 1300 - 1309
  • [8] Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
    Cunningham, John
    Block, Geoffrey A.
    Chertow, Glenn M.
    Cooper, Kerry
    Evenepoel, Pieter
    Iles, Jan
    Sun, Yan
    Urena-Torres, Pablo
    Bushinsky, David A.
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (07): : 987 - 994
  • [9] Treatment with Cinacalcet in Hemodialysis Patients with Severe Secondary Hyperparathyroidism, Influences Bone Mineral Metabolism and Anemia Parameters
    Aktsiali, Maria
    Papachrysanthou, Theodora
    Griveas, Ioannis
    Andriopoulos, Christos
    Sitaras, Panagiotis
    Triantafyllopoulos, Ioannis K.
    Lambrou, George, I
    CURRENT DRUG THERAPY, 2020, 15 (03) : 249 - 263
  • [10] Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism
    Yuan, Fang
    Chen, Xing
    Wang, Chang
    Li, Zheng
    Liu, Hong
    BLOOD PURIFICATION, 2018, 45 (1-3) : 73 - 78
12345